ImmunoPrecise Antibodies Ltd.
TSXV:IPA Stock Report
This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
ImmunoPrecise Antibodies Balance Sheet Health
Financial Health criteria checks 4/6
Key information
| Interest coverage ratio | n/a |
| Cash | CA$19.24m |
| Equity | CA$66.24m |
| Total liabilities | CA$13.70m |
| Total assets | CA$79.94m |
Recent financial health updates
We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully
Oct 20Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates
Dec 23Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?
Nov 25Financial Position Analysis
Short Term Liabilities: IPA's short term assets (CA$27.1M) exceed its short term liabilities (CA$5.4M).
Long Term Liabilities: IPA's short term assets (CA$27.1M) exceed its long term liabilities (CA$8.3M).
Debt to Equity History and Analysis
Debt Level: IPA is debt free.
Reducing Debt: IPA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IPA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IPA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 36% each year
Discover healthy companies
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
